マプロチリンによるakt/ mtorシグナル伝達経路の標的化は,T細胞リンパ腫における腫瘍抑制につながる
Xiaodong Li1, Jie Chen2, Riyi Zhang2
1Department of Clinical Laboratory, The Affiliated Li Huili Hospital, Ningbo University, 57 Xingning Road, Ningbo, 315000, China. lixiaodong4235@163.com.
Annals of hematology
|September 2, 2025
まとめ
抗うつ薬であるマプロチリンは,AKT/ mTOR経路を標的としてT細胞リンパ腫 (TCL) の成長と拡散を効果的に抑制します. この研究は,マプロチリンが
科学分野:
- 腫瘍学
- 薬理学について
- 分子生物学
背景:
- T細胞リンパ腫 (TCL) は,治療の選択肢が限られている重大な悪性腫瘍です.
- TCLの分子駆動因子と潜在的な治療標的は完全に理解されていません.
- マプロチリンはノレピネフリン再吸収阻害剤で,うつ病の治療に使われていますが,抗がん効果は未知のものです.
研究 の 目的:
- T細胞リンパ腫におけるマプロチリンの抗がん性について調べる.
- TCLにおけるマプロチリンの作用の基礎となる分子メカニズムを解明する.
- TCLの新たな治療戦略としてマプロチリンを研究する.
主な方法:
- 増殖,移住,アポトーシスを評価するためにTCL細胞系を用いたインビトロ研究.
- 腫瘍抑制と安全性を評価するためにTCL異種移植マウスモデルを用いた体内実験.
- AKT/mTOR信号経路の分析
- ヒストン脱酸化剤阻害剤との併用療法試験
主要な成果:
- マプロチリンは,TCL細胞の増殖と移動を著しく抑制し,同時にアポトーシスを誘導した.
- マプロチリン治療は腫瘍の進行を vivoで最小限の毒性で抑制した.
- マプロチリンはTCL細胞のAKT/ mTOR信号伝達経路を調節する.
- マプロチリンはヒストン減塩酵素阻害剤に対するTCL細胞の感受性を高めました.
結論:
- マプロチリンは強力な抗TCL活性を示し,新しい治療法を提示しています.
- AKT/ mTOR経路は,TCLにおけるマプロチリンの抗がん効果の重要な媒介である.
- マプロチリンは,T細胞リンパ腫の治療における有望な併用療法である.
関連する概念動画
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K


